Details of Disease

General Information of Disease (ID: DISFVG19)

• Disease Name: Prostate disease
• Synonyms: prostate gland disease or disorder; prostate gland disease; prostate disorder; prostate disease; disorder of prostate gland; disease or disorder of prostate gland; disease of prostate gland
• Disease Class: GA91: Prostate disease
• Definition: A disease involving the prostate gland.
• Disease Hierarchy:
  DISWD40R: Disease
  DISOEQW8: Male reproductive system disorder
  DISFVG19: Prostate disease
• ICD Code:
  ICD-11: ICD-11: GA91
  ICD-10: ICD-10: N42.9
• Disease Identifiers:
  MONDO ID: MONDO_0003105
  MESH ID: D011469
  UMLS CUI: C0033575
  MedGen ID: 10964
  SNOMED CT ID: 30281009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Plazomicin	DMKMBES	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FK-143	DMEL15U	Phase 2	Small molecular drug	[2]
FR-146687	DMGO45I	Phase 2	NA	[3]
Ozarelix	DMEGTH1	Phase 2	NA	[4]
Turosteride	DMW7PFS	Phase 2	Small molecular drug	[5]
RO-23-7553	DM9PQ2N	Phase 1	Small molecular drug	[6]

This Disease is Treated as An Indication in 11 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ONO-3805	DM1RKWV	Discontinued in Phase 3	Small molecular drug	[7]
FIDUXOSIN HYDROCHLORIDE	DMJRF5G	Discontinued in Phase 2	Small molecular drug	[8]
FINROZOLE	DM06SC9	Discontinued in Phase 2	Small molecular drug	[9]
GYKI-16084	DMMZQVS	Discontinued in Phase 2	Small molecular drug	[10]
JTH-601	DMQRKH4	Discontinued in Phase 2	Small molecular drug	[11]
L-771688	DMW8NOH	Discontinued in Phase 2	Small molecular drug	[12]
REC-15-2739	DMX4ZWK	Discontinued in Phase 2	Small molecular drug	[13]
SL-89.0591	DMOXUEP	Discontinued in Phase 2	NA	[14]
MK-0963	DMNAJGK	Discontinued in Phase 1	Small molecular drug	[15]
MK-434	DMERKWM	Discontinued in Phase 1	Small molecular drug	[16]
RS-100975	DM94R8B	Discontinued in Phase 1	Small molecular drug	[17]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GG-818	DMU82JV	Investigative	NA	[18]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
NOP2	TTBLG3H	Strong	Altered Expression	[19]
NPEPPS	TT371QC	Strong	Biomarker	[20]
SRD5A2	TTT02K8	Strong	Altered Expression	[21]
TMPRSS2	TT1GM2Z	Strong	Biomarker	[22]
SLC2A9	TTIF3GB	Definitive	Altered Expression	[23]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC30A4	DT280XI	Strong	Biomarker	[24]
SLC2A6	DTS4MKQ	Definitive	Altered Expression	[23]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
DHRS9	DEGTU5I	Strong	Biomarker	[25]
PSAT1	DEBS17P	Strong	Biomarker	[20]

This Disease Is Related to 11 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BRD8	OTIKS3PC	Strong	Altered Expression	[19]
ERG	OTOTX9VU	Strong	Biomarker	[22]
FMOD	OT9EJ5H8	Strong	Altered Expression	[26]
GLCE	OTPRSHX5	Strong	Altered Expression	[27]
HNRNPU	OTLQN1E2	Strong	Altered Expression	[19]
IGSF1	OT3XD6U2	Strong	Altered Expression	[19]
NAA25	OTS3QVF1	Strong	Altered Expression	[19]
NSUN5	OTBN7RS8	Strong	Altered Expression	[19]
OXT	OT48M72Z	Strong	Biomarker	[28]
PLAG1	OTT9AJQY	Strong	Biomarker	[20]
PROS1	OTXQWNOI	Strong	Biomarker	[20]

References

• [1] In vitro activity of plazomicin against -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003112)
• [3] Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol. 2002 Sep;54(3):283-94.
• [4] Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002567)
• [6] ClinicalTrials.gov (NCT00004926) ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy. U.S. National Institutes of Health.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003081)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012814)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010074)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010746)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010685)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014018)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003537)
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003628)
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003374)
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005411)
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 497).
• [18] In situ salt screening--a useful technique for discovery support and preformulation studies. Pharm Dev Technol. 1998 May;3(2):215-23.
• [19] A novel splice variant of the nuclear coactivator p120 functions strongly for androgen receptor: characteristic expression in prostate disease.Endocr J. 2008 Aug;55(4):657-65. doi: 10.1507/endocrj.k07e-133. Epub 2008 Jun 18.
• [20] Impact of total PSA and percent free PSA in the differentiation of prostate disease: a retrospective comparative study implicating neoplastic and non-neoplastic entities.J BUON. 2019 Sep-Oct;24(5):2107-2113.
• [21] DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate.Am J Pathol. 2015 Mar;185(3):870-82. doi: 10.1016/j.ajpath.2014.11.020. Epub 2015 Feb 17.
• [22] Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.Prostate. 2017 May;77(6):647-653. doi: 10.1002/pros.23312. Epub 2017 Jan 19.
• [23] Uric acid: a modulator of prostate cells and activin sensitivity.Mol Cell Biochem. 2016 Mar;414(1-2):187-99. doi: 10.1007/s11010-016-2671-8. Epub 2016 Feb 24.
• [24] Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer.Oncogene. 2003 Sep 4;22(38):6005-12. doi: 10.1038/sj.onc.1206797.
• [25] Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease.Mol Endocrinol. 2006 Feb;20(2):444-58. doi: 10.1210/me.2005-0287. Epub 2005 Sep 22.
• [26] Gene expression profiling of prostate cancer-associated genes identifies fibromodulin as potential novel biomarker for prostate cancer.Int J Biol Markers. 2016 May 28;31(2):e153-62. doi: 10.5301/jbm.5000184.
• [27] Heterogeneity of d-glucuronyl C5-epimerase expression and epigenetic regulation in prostate cancer.Cancer Med. 2013 Oct;2(5):654-61. doi: 10.1002/cam4.108. Epub 2013 Aug 5.
• [28] The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate.Prostate. 2007 Jul 1;67(10):1132-42. doi: 10.1002/pros.20612.